Literature DB >> 9664954

Conversion of renal transplant recipients from cyclosporin (neoral) to tacrolimus (prograf) for haemolytic uraemic syndrome.

G Morris-Stiff1, D Talbot, V Balaji, K Baboolal, K Callanan, J Hails, R Moore, D Manas, R Lord, W A Jurewicz.   

Abstract

Five patients with cyclosporin-related haemolytic uraemic syndrome (HUS) following cadaveric renal transplantation were converted from cyclosporin- to tacrolimus-based immunosuppression. All patients had biochemical, haematological and biopsy evidence of HUS at the time of conversion. Four of the patients showed complete resolution of the syndrome within 1 week of conversion with normalisation of haemoglobin, platelets and lactate dehydrogenase levels. In the fifth patient renal function stabilised with slow resolution of the haematological and biochemical parameters. Four of the five patients are still taking tacrolimus, one having converted back to cyclosporin due to marked hair loss. We conclude that conversion to tacrolimus appears to be an effective treatment for cyclosporin-related HUS following renal transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9664954     DOI: 10.1007/s001470050436

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  2 in total

1.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

2.  Thrombotic microangiopathy developing in early stage after renal transplantation with a high trough level of tacrolimus.

Authors:  Mitsuru Saito; Shigeru Satoh; Hideaki Kagaya; Hiroshi Tsuruta; Takashi Obara; Teruaki Kumazawa; Takamitsu Inoue; Kazuyuki Inoue; Masatomo Miura; Takeshi Yuasa; Atsushi Komatsuda; Norihiko Tsuchiya; Tomonori Habuchi
Journal:  Clin Exp Nephrol       Date:  2008-02-08       Impact factor: 2.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.